Xin Lang Cai Jing·2026-02-23 04:41Core Viewpoint - Spring Medical announced a significant increase in its 2025 annual performance, with a projected net profit growth of 96.01% to 130.41 million and a non-recurring net profit growth of 142.80% to 185.11 million, but the stock price has been declining due to the market's anticipation of this growth being already priced in [1][2] Stock Performance - Spring Medical's stock has shown weakness, with a maximum fluctuation of over 30% since reaching a high of 20.49 HKD in November 2025, dropping to a new low of 13.47 HKD by February 12, 2026 [1] - As of February 23, 2026, the stock price was 13.59 HKD, reflecting a slight increase of 0.07%, but a cumulative decline of 2.72% over the past five days [1] - In the past 60 days, net selling by Hong Kong Stock Connect has totaled 4.054 million shares, reducing the holding ratio from 47.77% in December 2025 to 43.16% in February 2026, resulting in a loss of over 10% [1] - The latest closing price in the A-share market was 22.27 CNY on February 13, 2026, with a daily increase of 0.68%, but a cumulative decline of 15.80% over the past 20 days [1] Financial Performance - The projected increase in 2025 performance is primarily driven by the release of growth potential in product lines post-collective procurement and the advancement of international business [2] - The significant growth in non-recurring net profit compared to net profit indicates an improvement in core business operations [2] - For the first three quarters of 2025, revenue reached 755.6 million CNY, representing a growth of 48.75%, while net profit attributable to shareholders was 192 million CNY, reflecting a substantial increase of 213.21% [2] - The international business has shown remarkable progress, with overseas revenue accounting for 40% of total revenue, shifting market focus towards the potential of overseas expansion as a key factor for stock price recovery [2]